REHOVOT, Israel and BRIDGEWATER, N.J., April 1, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced it has filed a registration statement with the Securities and Exchange Commission (SEC) for a proposed public offering of its ordinary shares. All of the shares will be offered by the company. Barclays Capital Inc., Cowen and Company, LLC and Guggenheim Securities, LLC are acting as book-running managers for the offering. Oppenheimer & Co. Inc. is acting as a co-manager. The offering of these securities will be made only by means of a written prospectus. A copy of the preliminary prospectus related to the offering, when available, may be obtained from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1 (888) 603-5847, or by emailing: Barclaysprospectus@broadridge.com; Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 631-274-2806, fax: 631-254-7140; or Guggenheim Securities, LLC, 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, telephone: (212) 518-9349 or by emailing: GSEquityProspectusDelivery@guggenheimpartners.com. A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Foamix Pharmaceuticals Ltd.Foamix is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne and other skin conditions. Foamix's lead product candidate, FMX101 for moderate-to-severe acne, is a novel topical foam formulation of the antibiotic minocycline. Foamix also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
CONTACT: Dov Tamarkin, CEO Foamix Pharmaceuticals Ltd. email@example.com +972-8-9316233 U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979